PubMed Health⌕ Search

Biomedical subjects

B Jarzab

Publications and source records attributed to B Jarzab.

At least 19 recordsLinked to original sources
PubMed1999

Corticotropin releasing hormone (CRH) increases beta-endorphin (beta-end like) concentration in cerebrospinal fluid of rats with vasospasm following subarachnoid hemorrhage.

The chronic stage of vasospasm occurring several days after subarachnoid hemorrhage (SAH) is characterized by the development of histopathologic changes in cerebral arteries causing cerebral ischemia. Numerous experimental data indicate the involvement of immune mechanisms in the angiopathy caused by SAH. Endogenous opioids play also an important role in the ischemic lesions of the brain. Corticotropin releasing hormone (CRH) induces the release of beta-endorphin (beta-END) from hypothalamic neurons and also from mononuclear white blood cells. The function of CRH and beta-END in vasospasm following SAH and the interrelationship between neuroendocrine and immune changes requires further elucidation. In the present study we investigated the influence of CRH injected into cerebral cisterna magna (CM) of rats on beta-END-like level in cerebrospinal fluid (CSF) in acute and chronic phase of cerebral vasospasm following artificial SAH. Acutely CRH induced a significant rise of beta-END-like in CSF both in SAH and sham SAH rats. However, in rats subjected to SAH, a single injection of CRH caused a prolonged rise of 5-END in CSF, which was also seen 2 days after SAH, during the chronic phase of vasospasm. The obtained results indicate that CRH increases neuroendocrine changes induced by SAH, probably by an activation of immune cells involved in the patomechanism of chronic vasospasm.

Acute Disease↗
PubMed1999

[The usefulness of MIBI scintigraphy for postoperative monitoring of patients with thyroid cancer].

Metoxyizobutyloizonitrile labelled with technetium 99mTc is a radio-pharmaceutical that was shown to accumulate in benign and cancerous thyroid tissue. As it can be applied without thyroid hormone withdrawal this gave a stimulus to the investigations on its usefulness in diagnostic and follow up procedures for thyroid cancer patients. The goal of this study is to evaluate the efficacy and benefit of 99mTc-MIBI whole body scintigrams in post surgery follow-up of patients with differentiated thyroid cancer. One hundred and twenty eight 99mTc MIBI scintigraphy were performed and evaluated. Sensitivity of MIBI scans was the highest for bone metastases--79%. Good results were also obtained for lymph node metastases (sensitivity--73%, specificity--90%). In case of lung metastases the sensitivity and specificity were 21% and 94% respectively. Sensitivity of detection of clinically apparent recurrent disease in thyroid bed was 70% and specificity of visualization 78%. Results of our study demonstrate that 99mTC-MIBI is valuable tool in follow up of thyroid cancer patients, but can not replace 131I scintygraphy.

Bone Neoplasms↗
PubMed1998

[Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases].

UNLABELLED: Serum concentrations of CA 19-9, CA 242, and CA 50 were determined in patients with hepatitis and liver cirrhosis without cholestasis. The study included 63 patients with chronic persistent hepatitis (group A), chronic active hepatitis (group B), and liver cirrhosis (group C). The control group (K) consisted of 82 patients with: peptic ulcer, colorectal polypi or diverticulosis of the colon. CA 19-9 level normal in the majority of patients with liver diseases, however, it was found to be increased in 4 (23%) of patients with liver cirrhosis. There was no statistically significant difference in the frequency of increased level of CA 19-9 between liver diseases and the control group. The rate of elevated serum level of CA 242 in patients with liver diseases and in control group was similar respectively 12%; 8.5%). The elevated CA 50 levels were most frequently found in patients with liver pathology (50% in liver cirrhosis and chronic active hepatitis; 36% in chronic persistent hepatitis). CONCLUSION: The elevation of CA 50 serum level occurs very often in liver diseases, even when they are going without cholestasis. Thus, the antigen is not useful for differentiating between benign and cancer diseases of gastrointestinal tract. Antigen CA 50 is to be taken into account only after exclusion of the pathology of liver, especially cirrhosis. Other investigated antigens: CA 19-9 and CA 242 are influenced by liver diseases to a minor and neglectable extent. Antigen CA 19-9 is the marker of choice in gastrointestinal cancers.

Adult↗
PubMed1997

[TSH-receptor antibodies in thyroid diseases].

The clinical usefulness of detection of TSH receptor antibodies (TRAK-assay, Henning) in differential diagnosis of thyroid disorders and in follow up of treatment of Graves' disease was evaluated and compared to thyroperoxidase antibodies estimation (DYNOtest antiTPO Henning). 313 patients with various thyroid diseases and 50 persons from control group were examined. Thyroperoxidase antibody (TPO-Ab) titers were frequently elevated in Graves' disease before treatment (88.6%, median 3361 U/ml) and in Hashimoto thyroiditis (100%, median 6055 U/ml). Median TPO-Ab was in normal range in other thyroid disorders and in control group (toxic nodular goiter: 58.5 U/ml, neutral nodular goiter: 46.0 U/ml, thyroid cancer after thyroidectomy: 58.8 U/ml, control group: 0 U/ml). TSH-receptor antibodies (TRAb) were detected in 94.1% in patients with Graves' disease (median 52 U/l) and only in 12.5% with Hashimoto disease (median 4.1 U/l), in 25% with toxic nodular goiter (median 4.1 U/l), in 10.9% with neutral nodular goiter (median 4.6 U/l) in 17.4% with thyroid cancer (median 1.6 U/l) and in 4.8% in control group (median 1.7 U/l). The TPO-Ab titers did not decrease significantly during thyrostatic treatment of Graves' disease. Patients in clinical remission after treatment exhibited TPO-Ab in 76.9% (median 615.5 U/ml). In contrast, the TRAb titers failed in patients treated with thyrostatics longer then six months (64%, median 16 U/l). After treatment 86.7% of them had normal values (median 1.0 U/l). The increase of TPO-Ab persisted in patients investigated two years after subtotal thyroidectomy (92.3%, median 750 U/ml). Only in patients operated before 10 years the titers declinedsignificantly (32%, median 43.4 U/ml). The TRAb titers fell significantly after thyroidectomy (two years: 62.5%, median 10.7% U/l, 10 years: 36.4%, median 4.2 U/l). Estimation of TRAb is a powerful tool for differential diagnosis of Graves' disease and enables better monitoring of the applied treatment than estimation of TPO-Ab.

Adolescent↗
PubMed1996

A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers.

We compared serum levels of CA 19-9 and CA 50 in 108 patients with malignant neoplasms of the stomach, pancreas, liver, and colon with the serum levels in 60 patients with benign gastrointestinal diseases, and 10 healthy subjects. Increased serum levels of CA 19-9 and CA 50 were found in 51.8 and 62% of the cancer patients, respectively. The results of CA 19-9 and CA 50 assays in the nonneoplastic group showed less specificity. False positive results were noted in 11.7% of CA 19-9 tests and in 31.6% of CA 50 tests. We concluded that in gastrointestinal cancer, the CA 19-9 test should be performed initially. CA 50 determination can be useful, but the lower specificity of the test should be taken into consideration. CA 50 should be recommended only for postoperative monitoring, especially in patients with normal CA 19-9 serum levels.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1995

[levels of erythropoietin in serum of patients with primary hyperparathyroidism].

UNLABELLED: The present study aimed assess the relationship between erythropoietin (EPO) and parathormone (PTH) secretion in patients with primary hyperparathyroidism (PHP). Seventeen patients with PHP and 24 patients with uncomplicated cholelithiasis were examined before and during 14 days after surgical treatment. In PHP patients plasma EPO levels were significantly higher than in patients with cholelithiasis (31.5 + 4.3 vs 14.1 + 0.9 mU/ml, p < 0.01). After cholecystectomy transient increase of plasma EPO level was noticed postoperatively during the first 6 days. Such an increase of plasma EPO was absent in PHP patients after removal of the cause of primary hyperparathyroidism. Only in PHP patients a significant negative correlation was found preoperatively between plasma EPO level and Hct value or creatinine clearance respectively. CONCLUSIONS: 1. Patients with PHP are characterized by significantly elevated plasma EPO levels which are related to the degree of anaemia and decrease of GFR. 2. In patients with PHP presence of significant relationship between EPO and PTH secretion could not be proven.

Adult↗
PubMed1993

[Changes of thyroid hormone levels in the perioperative period in patients with various types of goiter].

The thyroid hormone level was studied in the perioperative period in patients with various types of goitre. The clinical material comprised 85 patients treated surgically for nodular neutral goitre, nodular hyperactive goitre, Graves-Basedow disease, and cholecystolithiasis. The determination of total and free thyroid hormone blood serum levels was carried out in three periods of time, that is 4-5 days before operation, immediately after operation, and on the fifth day after operation. The obtained results led us to reaching the following conclusions: 1. Achieving of clinical euthyroid state in patients with Graves-Basedow disease during preoperative preparation with thyrostatic drugs was connected with the decrease of total and free thyroid hormone levels below the lower range of normal values which persisted immediately after, and on the 4th-5th day after operation. 2. During operation no significant increase was found of serum thyroid hormone levels. 3. On the 4th-5th day after operation, especially in patients with nodular neutral goitre and cholecystolithiasis a tendency was observed for a drop of triiodothyronine level, especially of its free fraction level.

Adult↗
PubMed1991

Influence of neurotransmitters on sexual differentiation of brain structure and function.

Newborn rats received daily subcutaneous treatment with compounds which influence serotoninergic, cholinergic, alpha-adrenergic and beta-adrenergic activity. In adulthood luteinizing hormone (LH) secretion pattern, female sexual behavior, and the volume of the sexually dimorphic nucleus of the preoptic are (SDN-POA) were determined. Postnatal administration of l-tryptophan increased the volume of the SDN-POA significantly when given alone or when given simultaneously with testosterone propionate (TP). Para-chlorophenyl-alanine (pCPA) also increased SDN-POA volume, but did not potentiate the stimulating influence of TP. Clonidine had no effect per se on SDN-POA development, but it significantly potentiated the effect of TP in females. Salbutamol increased SDN-POA volume in females and in males. Postnatal treatment of female rats with the alpha-adrenergic receptor antagonists prazosine and yohimbine or with the nicotin receptor antagonist mecamylamine had permanent potentiating effects on the pattern of LH secretion, whereas postnatal treatment with beta-adrenergic compounds reduced the LH-release response to gonadal steroids in adulthood. Postnatal treatment with clonidin or l-tryptophane inhibited differentiation of the capacity for lordosis behavior. Beta-receptor agonists postnatally had a potentiating effect on the capacity for lordosis behavior in female and male rats. Cholinergic stimulation postnatally inhibited differentiation of the capacity for lordosis behavior in female rats, but prevented the inhibitory effect of postnatal androgenization. There was no correlation between SDN-POA volume and any of the two functional parameters.

Animals↗
PubMed1991

[Migration inhibition test with thyroid membrane antigen in Graves-Basedow disease and nodular goiter].

The evaluation of the migration inhibition test with thyroid membrane antigen was carried out in 20 patients with Graves' disease, 13 patients with neutral nodular goiter and 13 healthy subjects. A significant inhibition of migration by thyroid antigen as compared to the control group was demonstrated only in the patients with Graves' disease (the value of the migration index was 0.57 +/- 0.07). The respective value was 0.79 +/- 0.16 in patients with nodular goiter and 0.85 +/- 0.11 in healthy subjects. The results obtained indicate the practical value of the migration inhibition test in diagnosing the thyroid diseases having an autoimmune background.

Adult↗
PubMed1990

Postnatal treatment of rats with the beta 2-adrenergic agonist salbutamol influences the volume of the sexually dimorphic nucleus in the preoptic area.

Sexual differentiation of the brain seems to be influenced by postnatal interaction of gonadal steroids with neurotransmitter systems, in particular the adrenergic system. Stimulation or inhibition of adrenergic receptors during early postnatal development had previously been shown to influence steroid-induced sexual differentiation of rat brain function. In the present study newborn male and female rats were treated daily for 5 days with salbutamol, a specific beta 2-receptor agonist, or with alprenolol, a beta-receptor antagonist and the volume of the sexually dimorphic nucleus of the preoptic area (SDN-POA) was examined in adulthood. This nucleus, one of the most striking sex differences in brain anatomy, is several-fold larger in male than in female rats. Postnatal treatment with salbutamol increased SDN-POA volume in female and in male rats. The effect was particularly striking in males, because any previous pre- and/or postnatal treatment of male rats with large amounts of gonadal steroids had been unable to increase the volume of the SDN-POA above normal. The beta-receptor antagonist alprenolol had no effect on SDN-POA differentiation. The results indicate that beta 2-adrenergic stimulation influences development and differentiation of the SDN-POA.

Albuterol↗
PubMed1989

Postnatal treatment of rats with beta-adrenergic agonists or antagonists influences differentiation of sexual brain functions.

Sexual differentiation of the brain seems to be influenced by postnatal interaction of gonadal steroids with neurotransmitter systems, in particular the adrenergic system. Stimulation or inhibition of alpha-adrenergic receptors during early postnatal development had previously been shown to influence steroid-induced sexual differentiation of brain functions. In the present study newborn male and female rats were treated either with salbutamol, a selective beta 2-adrenergic receptor agonist, isoprenaline, a general beta-adrenergic receptor agonist, or with alprenolol, a general beta-adrenergic receptor antagonist. In adulthood the female animals were ovariectomized and were tested for the capacity to show an LH-surge response and female sexual behaviour after priming with estradiol benzoate (EB) and progesterone (P). Male animals were tested for expression of male sexual behavior and, after gonadectomy and priming with EB + P, for the capacity to show female lordosis behavior. In summary, our results suggest that activation or inhibition of beta-adrenergic receptors during postnatal development permanently impairs the responsiveness of the center for cyclic gonadotropin release to gonadal steroids in female rats and impairs the expression of ejaculatory behavior in male rats. A slight stimulatory effect on the expression of female lordosis behavior was observed in male and female rats after postnatal activation of beta-adrenergic receptors.

Albuterol↗
PubMed1987

Postnatal treatment of rats with adrenergic receptor agonists or antagonists influences differentiation of sexual behavior.

The aim of the study was to investigate the possible role of the adrenergic system in development and differentiation of neural centers controlling sexual behavior in adulthood. For this purpose normal and androgenized female rats were treated with the alpha 1-receptor antagonist prazosin, the alpha 2-receptor agonist clonidine, or the alpha 2-receptor antagonist yohimbine-HCl throughout the first week of life. In adulthood all animals were ovariectomized and, after appropriate hormone-priming, they were tested for the capacity to display female and male sexual behavior patterns. Alteration of adrenergic transmission during the critical postnatal period for sexual differentiation of neural centers resulted in significant changes in the capacity to express female lordosis behavior in adulthood. In nonandrogenized animals clonidine significantly reduced the capacity for lordosis behavior. In androgenized animals clonidine had the opposite effect; it attenuated the inhibitory effect of testosterone propionate (TP) on differentiation of lordosis behavior. Prazosin, which was without effect in nonandrogenized animals, also attenuated the inhibitory effect of TP on differentiation of lordosis behavior. Yohimbine was without effect in androgenized and nonandrogenized animals. There was no influence of any of the adrenergic drugs on differentiation of male sexual behavior. In conclusion, differentiation of lordosis behavior seems to be mediated or modulated via adrenergic transmission. The defeminizing effect of testosterone postnatally on the differentiation of lordosis behavior seems to be expressed via alpha 1-adrenergic transmission, and diminished adrenergic activity during the postnatal period seems to protect the developing brain against this effect of testosterone.

Adrenergic alpha-Agonists↗
PubMed1987

Neonatal sex reversal of the brain and the urinary excretion of sex dependent proteins (SDP) in the rat.

In contrast to females adult male rats excrete a variety of low molecular weight sex dependent urinary proteins (SDP). Electrophoretic separation of these proteins yields at least 8 protein bands which are arranged in typical patterns. The present study was performed to investigate the effect of sexual differentiation, which can be influenced by neonatal hormone treatment, on production and excretion of the individual SDP-bands (I-VIII). Two major groups of rats were studied: one group was neonatally treated with testosterone propionate (TP, females) or cyproterone acetate (males). Another group of rats with or without neonatal TP-treatment were gonadectomized in adulthood and subsequently implanted with TP. The results demonstrated that SDP excretion is mainly related to the circulating plasma testosterone levels. The sexual differentiation of the brain, however, influences the quantity of SDP excreted which is especially evident for bands I and II. Neonatal cyproterone had influence on these two bands only. The results demonstrate that the hormonal mechanisms regulating the excretion of SDP varies in respect to the different protein bands. The functional role of sexual brain differentiation on the excretion of SDP and the detailed mechanisms by which the brain may control this excretion remain to be determined.

Alpha-Globulins↗
PubMed1986

Pre- and postnatal influence of an estrogen antagonist and an androgen antagonist on differentiation of the sexually dimorphic nucleus of the preoptic area in male and female rats.

The volume of the sexually dimorphic nucleus in the preoptic area (SDN-POA) of the rat brain is severalfold larger in adult male rats than in adult females. This sex difference in brain structure was previously shown to develop under the influence of androgenic and estrogenic hormones during the perinatal period. We tried to clarify the differential role played by androgens and estrogens during development and differentiation of the SDN-POA by treating male and female rats during an extended pre- and postnatal period either with the estrogen antagonist tamoxifen or with the androgen antagonist cyproterone acetate. Treatment with tamoxifen did not alter serum levels of testosterone in male rats during the perinatal period, but it inhibited development and differentiation of the SDN-POA. Pre- and postnatal treatment of male rats with cyproterone acetate resulted in female phenotypic appearance, but it had no influence on differentiation of the SDN-POA. Perinatal treatment of female rats with tamoxifen resulted in permanent anovulatory sterility, but did not influence SDN-POA differentiation. Treatment of female rats with cyproterone acetate had no influence on SDN-POA differentiation or on the capacity to ovulate. Since pre- and postnatal treatment of male rats with cyproterone acetate is known from previous studies to femenize sexual behavior patterns and to retain the mode for cyclic gonadotropin release, and since the same treatment did not influence differentiation of the SDN-POA in the present study, it may be concluded that the SDN-POA is not directly involved in the control of female sexual behavior and in the control of the gonadotropic hormone release pattern.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗